Technology

AriBio Hailed Success of Phase 3 Trial for ‘Oral Dementia Drug,’ but Related Stocks Plunge [Bio Spotlight]

Minji Son
2026-11-19 07:11:02
[Edaily Reporter Minji Son ] On the 17th, shares of domestic pharmaceutical, biotech, and healthcare companies experienced sharp fluctuations following the release of results from the global Phase 3 clinical trial of AriBio’s oral Alzheimer’s disease treatment candidate, “AR1001.”

In particular, #ARIBIOLAB and #AriBioHoldings hit their daily price limits, and SamjinPharmaceutical(005500)also plummeted. This was because while the primary endpoint was met in the monotherapy group for AR1001, statistical significance was not achieved in the overall patient population. Given the high expectations surrounding the clinical results, the failure to demonstrate efficacy in the overall patient population is believed to have dampened investor sentiment toward related stocks.
ARIBIOLAB stock price trend. (Source: KG Zeroin MP DOCTOR)

According to KG Zeroin MP Doctor (MP DOCTOR, formerly Marketpoint), ARIBIOLAB closed at 4,070 won on the KOSDAQ market today, down 29.95% (1,740 won) from the previous trading day.
AriBio Holdings stock price trend. (Source: KG Zeroin MP Doctor)

AriBio Holdings also closed regular trading at 2,560 won, down 29.86% (1,090 won).
SamjinPharmaceutical stock price trend. (Source: KG Zeroin MP Doctor)

SamjinPharmaceutical rose more than 11% in pre-market trading. Although it briefly climbed to 21,250 won during the session, it soon turned downward. The closing price was 17,030 won, down 15.48% (3,120 won) from the previous trading day.

These three listed companies are linked to AriBio, an unlisted firm that developed AR1001, through equity stakes or business relationships. In effect, expectations regarding clinical trials have been reflected in the stock prices of listed companies such as ARIBIOLAB, AriBio Holdings, and SamjinPharmaceutical, rather than in AriBio’s stock price.

ARIBIOLAB, formerly known as the Cha Vaccine Research Institute, conducts research and development in the vaccine and immunology fields. AriBio and AriBio Holdings secured stakes in ARIBIOLAB by participating in its paid-in capital increase. AriBio Holdings is a major shareholder of ARIBIOLAB and also holds a stake in AriBio. According to the semi-annual report, AriBio Holdings’ stake in AriBio stands at 13.42%.

SamjinPharmaceutical is the second-largest shareholder of AriBio, holding a 5.47% stake, and has entered into an agreement to jointly conduct the domestic Phase 3 clinical trial of AR1001 and to secure exclusive production and sales rights.

The global Phase 3 “POLARIS-AD” trial for AR1001 enrolled 1,535 patients with early-stage Alzheimer’s disease. Among the two predefined analysis subgroups, the 604 patients in the monotherapy group—who were not taking acetylcholinesterase inhibitors such as donepezil or existing symptomatic treatments such as memantine—showed a 0.44-point smaller change in the Clinical Dementia Rating Scale (CDR-SB) after 52 weeks compared to the placebo group. This difference was statistically significant (p=0.0266). In contrast, among the overall patient population, the difference was only 0.11 points and did not reach statistical significance (p=0.4015).

The clinical trial designated the overall patient population and the monotherapy group as pre-specified primary analysis populations. The design was structured such that the primary endpoint would be met if either group met the pre-specified statistical criteria. Aribio announced that it had achieved its Phase 3 clinical trial objectives based on the results from the monotherapy group. However, the market appears to be focusing on the fact that efficacy was not demonstrated in the overall patient population and on whether approval and commercialization can proceed based solely on the results from the monotherapy group.

In a Seohan issued that day, Aribio emphasized the achievements based on the monotherapy group’s results. The company stated, “We achieved statistical significance in the monotherapy group, which was designated in advance through consultation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA),” adding, “We have thus met the primary endpoint, which is the criterion for the success of the Phase 3 clinical trial.” The company added, “Management believes that we can proceed with an FDA approval application based solely on the results from the monotherapy group,” and noted, “We will finalize the specific approval pathway and requirements in consultation with the FDA.”

An AriBio official said, “The extension study is currently underway and is scheduled to continue through June of next year,” adding, “We also plan to continue additional analyses, including sub-endpoints and biomarkers.” The official emphasized, “We do not view this clinical trial as a failure,” explaining, “The design calls for evaluating both the overall patient population and the monotherapy group separately; if either meets the criteria, the primary endpoint is considered achieved.” The company also plans to begin pre-NDA meetings with regulatory agencies, such as the FDA and EMA, to discuss the application process.

The company also highlighted the convenience of AR1001 compared to existing treatments. In a Seohan to shareholders, the company noted that compared to Lecanemab (brand name Lecembi), a treatment currently on the market, “(Lecanemab) requires an intravenous injection every two weeks or a subcutaneous injection every week,” and “patients must undergo regular MRI scans to check for cerebral edema or microbleeds (ARIA).”

The company added, “AR1001 is a once-daily oral tablet, allowing patients to continue treatment as part of their daily routine without having to make repeated trips to the hospital for injections.”

In fact, there have been precedents where FDA approval was granted for a specific patient subgroup after results were mixed between the overall population and that subgroup. Eli Lilly’s breast cancer treatment “Inluryo” (generic name: imrunestrant) showed no statistically significant improvement in progression-free survival (PFS) for the overall patient population in Phase 3 trials, but demonstrated a significant improvement in the pre-specified subgroup of patients with ESR1 mutations. Last year, the FDA limited approval to patients with ESR1-mutated advanced or metastatic breast cancer.

Befdegestrant, a breast cancer treatment jointly developed by Pfizer and Avinas, also failed to meet the significance threshold for PFS improvement in the overall patient population during Phase 3 clinical trials, but demonstrated a significant effect in the ESR1-mutant patient subgroup. The FDA approved this drug this year for patients with ESR1-mutant advanced or metastatic breast cancer.

A representative from SamjinPharmaceutical stated, “The domestic approval process is also an area that must be led by AriBio,” adding, “We plan to discuss the domestic commercialization roadmap depending on how AriBio outlines its future plans.”

Economy

Corporation

IT·Science

Economy

Will Stock Prices Rise If Acquisition Thresholds Are Lowered?…The Dilemma of Hostile M&A

As the government considers hostile mergers and acquisitions (M&A) as a means to enhance corporate value, calls are growing for the establishment of institutional safeguards before revitalizing the ac…
2026-11-19 06:50:04

Corporation

SamyangFoods’ Holding Company Establishes Wind Power Subsidiary in Pyeongchang… Pursuing New Mid- to Long-Term Business Ventures

Samyang Round Square, the holding company of SamyangFoods(003230), has established a wind power generation subsidiary in Pyeongchang, Gangwon Province. This move is intended to pursue a “repowering” p…
2026-11-18 18:14:36

IT·Science

AriBio Announces Success in Phase 3 Trials for Oral Alzheimer's Drug, but Related Stocks Plunge [K-Bio Pulse]

South Korean pharmaceutical, biotech, and healthcare stocks experienced a turbulent trading session on November 17 as the release of global Phase 3 trial results for AriBio’s oral Alzheimer’s disease …
2026-11-19 07:12:03